Nk Cell Therapy Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., I

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nk Cell Therapy pipeline constitutes key companies continuously working towards developing Nk Cell Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Nk Cell Therapy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nk Cell Therapy Market.

The Nk Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Nk Cell Therapy Pipeline Report: https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Nk Cell Therapy treatment therapies with a considerable amount of success over the years.
• Nk Cell Therapy companies working in the treatment market are ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others, are developing therapies for the Nk Cell Therapy treatment
• Emerging Nk Cell Therapy therapies such as - ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others are expected to have a significant impact on the Nk Cell Therapy market in the coming years.
• In February 2022, In order to evaluate the effectiveness and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC who have not progressed after platinum-based cCRT, AstraZeneca started a Phase III, randomised, double-blind, multi
• In June 2022, A randomised, placebo-controlled, open-label, phase IIb clinical trial was started by SMT Bio Co., Ltd. to compare the anticancer effects of pembrolizumab monotherapy and combination therapy for patients with advanced biliary tract cancer. In patients with advanced biliary tract cancer, the goal of this study is to compare the anticancer effects of pembrolizumab monotherapy and combination therapy using SMT-NK (allogeneic natural killer cells)
• In April, 2022 The Phase III clinical trial PACIFIC-9, which is evaluating durvalumab (anti-PD-L1) in combination with monalizumab (AstraZeneca's oleclumab, anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC), reported a $50 million milestone payment from AstraZeneca was triggered for dosing the first patient
• In August 2022, An efficacy criterion for the INTERLINK-1 Phase III research, which was financed by AstraZeneca (LSE/STO/Nasdaq: AZN), was not met, according to an announcement from Innate Pharma SA. AstraZeneca has informed Innate that the trial would be terminated in light of this result and the advice of an Independent Data Monitoring Committee
• In October 2020, A randomised, double-blind, multicenter, international Phase 3 research was started by Innate Pharma and AstraZeneca to compare the effectiveness and safety of monalizumab and cetuximab versus placebo and cetuximab in patients with recurrent or metastatic head and neck cancer
• In December 2019, For patients with Gemcitabine-refractory Biliary Tract Cancer, SMT Bio Co., Ltd. initiated a Phase I/IIa clinical research to assess the safety and efficacy of allogeneic NK cells in conjunction with pembrolizumab. The trial had 40 participants and was finished in June 2021

Nk Cell Therapy Overview
Natural killer cells, usually referred to as NK cells, are an important subset of lymphocytes that make up the innate immune system. They are extremely specialised predators that have a significant impact on how the host rejects tumours and virally infected cells. Granzymes, or cytotoxic tiny granules, are found in the cytoplasm of NK cells and include unique proteins such perforins and proteases.

Get a Free Sample PDF Report to know more about Nk Cell Therapy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Nk Cell Therapy Drugs Under Different Phases of Clinical Development Include:
• ONKT102: ONK Therapeutics
• CAT-:179 Catamaran Bio
• NKTR-214: Nektar therapeutics
• Bemarituzumab: Five Prime Therapeutics
• ALT 803: ImmunityBio
• CellProtect: XNK Therapeutics
• K-NK002: Kiadis Pharma
• NK-92: ImmunityBio
• WU-NK-101: Wugen
• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
• ALECSAT: CytoVac
• CHM 0201: Chimeric Therapeutics
• GDA-201: Gamida-Cell
• AB 101: Artiva Biotherapeutics
• DF1001: Dragonfly therapeutics
• AFM13: Affimed
• Evencaleucel: XNK Therapeutics
• GTA002: Glycostem
• BVAC-C: CELLID
• SMT-NK: SMT bio Co., Ltd.
• Monalizumab: Innate Pharma

Route of Administration
Nk Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Nk Cell Therapy Pipeline Therapeutics Assessment
• Nk Cell Therapy Assessment by Product Type
• Nk Cell Therapy By Stage and Product Type
• Nk Cell Therapy Assessment by Route of Administration
• Nk Cell Therapy By Stage and Route of Administration
• Nk Cell Therapy Assessment by Molecule Type
• Nk Cell Therapy by Stage and Molecule Type

DelveInsight's Nk Cell Therapy Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Nk Cell Therapy product details are provided in the report. Download the Nk Cell Therapy pipeline report to learn more about the emerging Nk Cell Therapy therapies at:
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Nk Cell Therapy Therapeutics Market include:
Key companies developing therapies for Nk Cell Therapy are - Abivax, Acepodia, Affimed Therapeutics AG, Agenus, Allife Medical Science and Technology, Artiva Biotherapeutics, Asclepius Technology Company Group, Bellicum Pharmaceuticals, Bright Path Biotherapeutics, Bristol-Myers Squibb, Cantargia, CARsgen therapeutics, Celgene Corporation/Celularity, Cellid Company, Celularity, Celyad Oncology, Chongqing Sidemu Biotechnology, CiMass, CureTech, CytoImmune Therapeutics, CytoVac, Cytovia Therapeutics, Dragonfly Therapeutics, Dynavax, Exacis Biotherapeutics, Fate Therapeutics, Feldan Therapeutics, Five Prime Therapeutics, Glycostem, Glycostem Therapeutics (IPD Therapeutic), Green Cross Corporation, GT Biopharma, HiberCell, iCell Gene Therapeutics, ImmunityBio, Innate Pharma, Kiadis Pharma, Kuur Therapeutics (Formerly Cell Medica), Multimmune GmbH, NantKwest, Nektar Therapeutics, NKMax, ONK Therapeutics, Orgenesis, PersonGen BioTherapeutics (Suzhou), Surface Oncology, Synimmune, Vycellix, XNK Therapeutics, and others.

Nk Cell Therapy Pipeline Analysis:
The Nk Cell Therapy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Nk Cell Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nk Cell Therapy Treatment.
• Nk Cell Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nk Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nk Cell Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Nk Cell Therapy drugs and therapies-
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Nk Cell Therapy Pipeline Market Drivers
• Increase in clinical and pre-clinical research with positive results, increase in collaborations and acquisitions between companies, increasing interest towards NK Cell Therapies among biotech and pharma companies, enhanced efficacy of NK Cells are some of the important factors that are fueling the Nk Cell Therapy Market.

Nk Cell Therapy Pipeline Market Barriers
• However, Short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.

Scope of Nk Cell Therapy Pipeline Drug Insight
• Coverage: Global
• Key Nk Cell Therapy Companies: ONK Therapeutics, Catamaran Bio, Chimeric Therapeutics, Gamida-Cell, Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeutics, Glycostem, CELLID, SMT bio Co., Ltd., Innate Pharma, and others
• Key Nk Cell Therapy Therapies: ONKT102, CAT-179, CHM 0201, GDA-201, AB 101, DF1001, AFM13, Evencaleucel, GTA002, BVAC-C, SMT-NK, Monalizumab, and others
• Nk Cell Therapy Therapeutic Assessment: Nk Cell Therapy current marketed and Nk Cell Therapy emerging therapies
• Nk Cell Therapy Market Dynamics: Nk Cell Therapy market drivers and Nk Cell Therapy market barriers

Request for Sample PDF Report for Nk Cell Therapy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Nk Cell Therapy Report Introduction
2 Nk Cell Therapy Executive Summary
3 Nk Cell Therapy Overview
4 Nk Cell Therapy- Analytical Perspective In-depth Commercial Assessment
5 Nk Cell Therapy Pipeline Therapeutics
6 Nk Cell Therapy Late Stage Products (Phase II/III)
7 Nk Cell Therapy Mid Stage Products (Phase II)
8 Nk Cell Therapy Early Stage Products (Phase I)
9 Nk Cell Therapy Preclinical Stage Products
10 Nk Cell Therapy Therapeutics Assessment
11 Nk Cell Therapy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Nk Cell Therapy Key Companies
14 Nk Cell Therapy Key Products
15 Nk Cell Therapy Unmet Needs
16 Nk Cell Therapy Market Drivers and Barriers
17 Nk Cell Therapy Future Perspectives and Conclusion
18 Nk Cell Therapy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Nk Cell Therapy Market https://www.delveinsight.com/report-store/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Nk Cell Therapy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.